4e1rcat

4E1RCat is a dual inhibitor of eIF4E:eIF4 g and eIF4E:4E-BP1 interaction. And it inhibits the binding of eIF4 g to eIF4E with IC50 of 3.2 μM.

4E1rcat 17d features a core structure of (E)-3-(2-furanmethylmethylene)-2-pyrrolidone, and its analog 4E1rcat blocked the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays with IC50 values of 1.1 μM and 1.7 μM, respectively.

4E1rcat 27d (Compound 27d) contains a core structure of (E)-3-(2-furanylmethylene)-2-pyrrolidinone. Its analog 4E1rcat blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays, with IC₅₀ values of 1.1 μM and 1.7 μM, respectively.

4E1rcat analogue 1 has a core structure of (E)-3-(2-furanmethylmethylene)-2-pyrrolidone, and its analog 4E1rcat blocked the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays with IC50 values of 1.1 μM and 1.7 μM, respectively.

4E1rcat analogue 2 has a core structure of (E)-3-(2-furylmethylene)-2-pyrrolidinone, and its analog 4E1rcat blocks the interactions between ATG5–ATG16L1 and ATG5–TECAIR in in vitro binding assays, with IC₅₀ values of 1.1 μM and 1.7 μM, respectively.

4E1rcat analogue 3 has a (E)-3-(2-furanylmethylene)-2-pyrrolidinone core structure, and its analog 4E1rcat blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays with IC50 values of 1.1 μM and 1.7 μM, respectively.

4E1rcat analogue 4 has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. Its analogue 4E1rcat blocked the interaction between ATG5-ATG16L1 and ATG5-TECAIR in the in vitro binding assay, with IC50 values of 1.1 μM and 1.7 μM respectively.

4E1rcat analogue 5 possesses a core structure of (E)-3-(2-furanylmethylene)-2-pyrrolidinone. Its parent compound 4E1rcat blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays, with IC₅₀ values of 1.1 μM and 1.7 μM, respectively.

4E1rcat analogue 6 has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. Its analogue 4E1rcat blocked the interaction between ATG5-ATG16L1 and ATG5-TECAIR in the in vitro binding assay, with IC50 values of 1.1 μM and 1.7 μM respectively.

4E1rcat analogue 7 possesses an (E)-3-(2-furylmethylene)-2-pyrrolidone core structure. Its analog 4E1rcat blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays, with IC50 values of 1.1 μM and 1.7 μM, respectively.

4E1rcat analogue 8 has a core structure of (E)-3-(2-furylmethylene)-2-pyrrolidinone, and its analog 4E1rcat blocks the interactions between ATG5–ATG16L1 and ATG5–TECAIR in in vitro binding assays, with IC₅₀ values of 1.1 μM and 1.7 μM, respectively.

4E1rcat analogue 9 has an (E)-3-(2-furylmethylene)-2-pyrrolidone core structure. Its analog 4E1rcat blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays, with IC50 values of 1.1 μM and 1.7 μM, respectively.